Intro to COVID-19: Defining Emergency Use Authorization (EUA) Authorities
This session will address general regulatory requirements for bringing a medical product to market under emergency use authorities in the Federal Food, Drug, and Cosmetic Act.
Cathy L. Burgess, Partner, Alston & Bird LLP, Member, FDLI Board of Directors
This session was recorded as part of FDLI’s virtual course, “COVID-19: Introduction to FDA’s Existing Legal Authorities and Emerging Issues” in August 2020.
Get Access
- +$100 for nonmembers
Virtual Learning FAQ
On-demand webinar content is sent via email as soon as we are able to process and verify your order. This usually occurs within 1 business day.
On-demand content can be played back on most devices.
CLE credit is not currently available for pre-recorded sessions.
Related Content